SUMMARY Because thromboxane synthesis enhances gastric mucosal damage we have investigated whether the thromboxane synthesis inhibitor dazmegrel might be protective to the mucosa. Dazmegrel at a dose of 1 and 5 mg per rat (4.8 and 23-8 mg/kg) significantly reduced the damage caused by acidified taurocholate. In parallel experiments dazmegrel exerted a selective and dose dependent inhibition of ex vivo thromboxane synthesis by gastric fragments over the dose range in which protection was observed. As dazmegrel can be given to man, these experiments suggest that investigation of mucosal protection would be justified.
At present there is considerable interest in the use of prostaglandins to treat peptic ulceration and in the role of 'cytoprotection' of the gastroduodenal mucosa in this process.' Exogenous prostaglandins can prevent or limit gastric mucosal damage provoked by ethanol, bile acids and non-steroidal anti inflammatory drugs in the rat'2 and there are more limited comparable data in man.' There is growing evidence that similar protection can be achieved by stimulating endogenous prostaglandin synthesis. ' In contrast with the E and I prostaglandins, thromboxane A2 has properties which can be detrimental to gastric mucosal integrity. Thromboxane A2 is vasoconstrictor and enhanced synthesis produced by continuous infusion of arachidonic acid causes the rapid development of extensive gastric erosions in chambered rat stomachs exposed to acidified taurocholate.' This damage could be prevented by the use of benzyl imidazole, a thromboxane synthethase inhibitor. We have therefore investigated the protective potential of dazmegrel ( Fig. 1 
Methods

MATERIALS
Dazmegrel (3-(-IH-imidazol-l-yl-methyl)-2-methyl-IH-indole-1-propanoic acid, MW283) was supplied by Pfizer UK Ltd and used at three concentrations (2 mg/ml, 10 mg/ml, and 50 mg/ml) in phosphate buffered saline (PBS), 005 M pH 7*4.
Prostaglandin El was supplied by Upjohn, Kalamazoo and made up to 150 mg/ml in PBS from ethanolic stock solutions (1 mg/ml). Sodium taurocholate (Sigma UK) was dissolved in 0-2 N hydrochloric acid to a final concentration of 100 mM. All solutions were freshly prepared immediately before the start of each experiment and coded to ensure that the investigator was unaware of their identities. Male Wistar rats weighing between 200 and 220 g were used in all experiments. The rats were housed in restraining cages to prevent coprophagy, were fasted for 20 hours and were deprived of water for four hours before each group of experiments.
GASTRIC MUCOSAL DAMAGE
Groups of rats were treated as shown in Figure 2 .
Dazmegrel in PBS or PBS alone were administered by gavage in volumes of 0-5 ml through a 5 FG orogastric tube. Three doses of dazmegrel were used, 1 mg/rat (4.8 mg/kg, n=8), 5 mg/rat (23-8 mg/kg, n=8) and 25 mg/rat (119 mg/kg, n=8). Two hours later 1 ml acidified taurocholate or distilled water was administered by gavage and after a further hour the animals were killed by CO2 narcosis. Seven rats were pretreated with PGEI, 75 [tg in 0*5 ml PBS 15 minutes before acidified taurocholate and killed one hour later. In each experiment positive control (PBS followed by taurocholate) and negative controls (PBS followed by water) were included.
ASSESSMENT OF DAMAGE
After death the stomachs were carefully removed, and opened along the greater curve, and flattened on glass. Damage was assessed by two observers independently, using a numerical grading score of 0-4. Grade 0 was no macroscopic abnormality, grade 1 
Results
The rats were in good general condition before being killed and no rat died during any procedure.
GASTRIC MUCOSAL DAMAGE
The degree of mucosal damage was decreased by treatment with dazmegrel (Fig. 3) . The median (range) grade of damage was 2.5 (2-4) with placebo (n=8) and fell to 1 5 (0-3) with dazmegrel 1 mg (n=8, p<005) and to 1 (0-3) with dazmegrel 5 mg (n=8, p<001) and to 2 (0-5-3-5) with dazmegrel 25 mg (n=8, NS and a thromboxane receptor antagonist has now been reported in studies with rats.46 4 In addition we have investigated the biochemistry of the 'cytoprotective' drug WHR2348A and shown it to be a powerful and specific inhibitor of thromboxane synthesis in the gastric mucosa.'5 Taken as a whole, this evidence emphasises the importance of thromboxane synthesis in the gastric mucosa, and the therapeutic potential of TXSIs. The possibility that similar mechanisms are involved in the apparent 'cytoprotective' properties of such compounds as bismuth'6 sucralfate'7 or cimetidine" would be worth investigating.
The precise clinical significance of our observations remains to be determined, as the contribution of 'cytoprotection' to ulcer healing by prostaglandins is currently undecided.' Inhibition of thromboxane synthesis, however, represents a novel approach to the development of possible ulcer healing agents which warrants further investigation. Likewise the enhancement of mucosal integrity achieved by TXSIs could be of value for maintenance treatment after healing of peptic ulcers. The particular interest of dazmegrel is that it has been given to man for prolonged periods without adverse effects. Our observations therefore justify further assessment of dazmegrel's mucosal protective properties in man using established techniques to measure microscopic bleeding2" or cellular exfoliation. 
